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Interrater Reliability of Surveillance for Ventilator-Associated
Events and Pneumonia
Meeta Prasad Kerlin, MD, MSCE;1 William E. Trick, MD;2 Deverick J. Anderson, MD, MPH;3
Hilary M. Babcock, MD;4 Ebbing Lautenbach, MD, MPH, MSCE;1 Renaud Gueret, MD;2
Michael Klompas, MD, MPH5,6 for the CDC Prevention Epicenters
objective. To compare interrater reliabilities for ventilator-associated event (VAE) surveillance, traditional ventilator-associated
pneumonia (VAP) surveillance, and clinical diagnosis of VAP by intensivists.
design. A retrospective study nested within a prospective multicenter quality improvement study.
setting. Intensive care units (ICUs) within 5 hospitals of the Centers for Disease Control and Prevention Epicenters.
patients. Patients who underwent mechanical ventilation.
methods. We selected 150 charts for review, including all VAEs and traditionally deﬁned VAPs identiﬁed during the primary study and
randomly selected charts of patients without VAEs or VAPs. Each chart was independently reviewed by 2 research assistants (RAs) for VAEs,
2 hospital infection preventionists (IPs) for traditionally deﬁned VAP, and 2 intensivists for any episodes of pulmonary deterioration.
We calculated interrater agreement using κ estimates.
results. The 150 selected episodes spanned 2,500 ventilator days. In total, 93–96 VAEs were identiﬁed by RAs; 31–49 VAPs were identiﬁed
by IPs, and 29–35 VAPs were diagnosed by intensivists. Interrater reliability between RAs for VAEs was high (κ, 0.71; 95% CI, 0.59–0.81).
Agreement between IPs using traditional VAP criteria was slight (κ, 0.12; 95% CI, −0.05–0.29). Agreement between intensivists was slight
regarding episodes of pulmonary deterioration (κ 0.22; 95% CI, 0.05–0.39) and was fair regarding whether episodes of deterioration were
attributable to clinically deﬁned VAP (κ, 0.34; 95% CI, 0.17–0.51). The clinical correlation between VAE surveillance and intensivists’ clinical
assessments was poor.
conclusions. Prospective surveillance using VAE criteria is more reliable than traditional VAP surveillance and clinical VAP diagnosis;
the correlation between VAEs and clinically recognized pulmonary deterioration is poor.
Infect Control Hosp Epidemiol 2017;38:172–178
Ventilator-associated pneumonia (VAP) is a complication of
mechanical ventilation associated with signiﬁcant morbidity,
including prolongation of mechanical ventilation, increased
ICU and hospital lengths of stay, and higher mortality rates.1
For many years, the National Healthcare Safety Network
(NHSN) of the Centers for Disease Control and Prevention
(CDC) encouraged hospitals to conduct surveillance for VAP
using a deﬁnition that required patients to fulﬁll radiographic,
systemic, and pulmonary criteria. However, surveillance using
this deﬁnition was labor-intensive, nonspeciﬁc, and highly
subjective.2,3 To address these issues, the CDC created a new
deﬁnition for ventilator-associated events (VAEs), including
nested categories for ventilator-associated conditions (VACs),
infection-related ventilator-associated complications (IVACs),
and possible pneumonia (Figure 1).4
VAE deﬁnitions were designed to increase the objectivity
and reproducibility of surveillance by using quantitative rather
than qualitative clinical data and by providing clear formulas
on how to combine these data to meet VAE criteria. It is
unknown, however, whether VAE surveillance in practice is
more reproducible and consistent than surveillance using the
NHSN’s traditional VAP deﬁnitions. Some concerns about
VAE surveillance have been raised. Klouwenberg et al5
demonstrated that different strategies for deﬁning the daily
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minimum positive end expiratory pressure (PEEP) (eg, mini-
mum per minute, minimum per hour, minimum sustained for
at least 1 hour, or 10th percentile) identiﬁed different episodes
as VAEs. Mann et al6 demonstrated that manual surveyors
make mistakes when applying VAE criteria and that different
manual surveyors capture different cases relative to one
another and to automated surveillance systems.
Given that VAE deﬁnitions have been proposed as possible
quality improvement and benchmarking metrics, it is impor-
tant to quantify the reliability and reproducibility of VAE
surveillance. We compared the interrater reliability of VAE
surveillance to the interrater reliability of NHSN’s former VAP
deﬁnition and to the clinical diagnosis of VAP by practicing
intensivists. We hypothesized that interrater reliability for
VAE would be high and better than interrater reliability for




This retrospective chart-review study was nested within the
CDC Prevention Epicenters’ Wake-Up-and-Breathe study.7
Brieﬂy, the Wake-Up-and-Breathe study was a multicenter
prospective evaluation of a multidisciplinary opt-out protocol
for daily sedative interruptions and spontaneous breathing
trials conducted in 2011–2013, for which the primary
study outcome was VAE rates. The study included 20 ICUs
in 13 academic and community hospitals afﬁliated with
5 academic centers of the CDC Prevention Epicenters’
Collaborative. The study tracked 5,164 consecutive episodes of
mechanical ventilation over a 19-month period.
Study Population
We selected 30 patients from each of the 5 participating
Epicenter sites for the current study. Given the rarity of both
VAEs and traditionally deﬁned VAPs, each site included all VAEs
and all traditionally deﬁned VAPs in their sample and then
randomly selected the balance of patients (for a net total of
30 patients) from the population of patients ventilated for
≥10 days. A 10-day minimum was selected for these patients to
enrich the study sample with patients more likely to have
suffered respiratory complications. The sample size was selected
for feasibility. Each Epicenter designated 1 or more of their ICUs
enrolled in theWake Up and Breathe Collaborative to include in
this substudy based on ease of access to records.
Chart Reviews
All charts from all sites were independently reviewed by
2 research assistants (RAs) for VAEs (the primary RA for the
prospective study and a second RA for this chart review), by
2 infection preventionists (IPs) for traditionally deﬁned VAPs8
(the primary IP for the prospective study and a second IP for
ﬁgure 1. Ventilator-associated events as deﬁned at the time of the study in 2014. The pneumonia tier has been modiﬁed slightly since
then. Reprinted with permission of the American Thoracic Society. Copyright ©2016 American Thoracic Society.7 The American Journal of
Respiratory and Critical Care Medicine is an ofﬁcial journal of the American Thoracic Society.
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this chart review), and by 2 intensivists for clinical events
compatible with VAP. All reviewers were blinded to patient
VAE and VAP status as identiﬁed in the primary study and to
each other’s determinations. All data were collected using
web-based forms that were centrally collated at the study’s data
coordinating center (Medical Research Analytics and
Informatics Alliance [MRAIA], Chicago, IL).
The 2 RA VAE reviewers abstracted daily minimum PEEP
and daily minimum FiO2s from patient charts. One RA
reviewed charts as part of the primary, prospective study, and
the other RA was provided the dates of mechanical ventilation
and was asked to review charts retrospectively after the
primary study had ended. Values were entered into the web-
based data collection tool that then automatically identiﬁed
VAEs using CDC criteria.9 For both reviewers, if the website
ﬂagged a VAE, the reviewers were asked to also enter the
patient’s minimum and maximum daily temperatures, white
blood cell count, and daily antibiotic exposure to assess for
IVAC. When available, microbiology results were entered to
assess for possible pneumonia. All laboratory testing was per-
formed at the discretion of the treating clinicians subject to the
individual protocols of the ICU and was not inﬂuenced by the
research team.
The 2 IPs were asked to identify episodes of VAP using
the NHSN then-current PNEU criteria. One IP reviewed
charts as part of routine operational surveillance, and the other
was provided the dates of mechanical ventilation and asked to
review charts retrospectively, as with the RAs. NHSN trainers
provided a webinar-based refresher course on PNEU surveil-
lance for all IPs.
All prospective RA reviewers were trained together in data
collection and VAE surveillance by the primary research staff
via webinar. All retrospective RA reviewers were trained on an
ad hoc basis by members of the research team at their local
institutions. None of the reviewers (RAs or IPs, prospectively
or retrospectively) had any contact with bedside providers
during surveillance activities. All reviewers had access to the
same data, including paper medical charts and electronic
health records.
The 2 intensivists (board-eligible or board-certiﬁed critical
care specialists) were provided with the dates for each patient’s
designated episode of mechanical ventilation and reviewed the
charts retrospectively after the primary study had ended.
They were asked to determine whether the patient had had an
episode of “respiratory deterioration,” and if so, to select its
cause from a list of possible causes that included VAP. They
were asked to use their expert opinion to deﬁne deterioration
as well as the possible cause(s) of deterioration without further
guidance, as our objective was to understand the practical
clinical correlates of VAEs and VAPs. The intensivists
were permitted to review any part of a patient’s chart to the
extent they felt necessary to make their assessment, including
physiologic and lab data, diagnostic imaging, and clinical
notes. Intensivists documented their assessment on an
encrypted web form.
Statistical Analysis
We summarized the characteristics of included patients using
standard descriptive statistics. We assessed interrater reliability
(1) to identify VAEs according to the 2 RAs; (2) to identify
VAP per the prior NHSN deﬁnition by the 2 IPs, (3) to identify
any pulmonary deterioration event during the episode of
mechanical ventilation according to the intensivist reviewers;
(4) to determine the primary cause of pulmonary deterioration
according to the intensivist reviewers; (5) to determine the
primary cause of pulmonary deterioration due to VAP
according to the intensivist reviewers, and (6) to identify any
episode of pulmonary deterioration according to the intensi-
vist reviewers versus VAE by the primary study RA. In this last
category, we chose to compare intensivists’ assessments to
VAE classiﬁcations by the primary study RA because the study
RAs received the most robust training and supervision on VAE
surveillance; thus, we felt their assessments were closest to a
gold standard for identiﬁcation of VAEs.
Primary estimates of agreement were performed at the level
of a respiratory event (eg, VAE according to study RAs, VAP
according to IP, and respiratory deterioration according to
intensivist reviewers). We considered reviewers to be in
agreement if events identiﬁed by each rater were within 2 days
of each other or if no events were identiﬁed for a given patient,
considering that episodes of mechanical ventilation varied in
duration and that multiple events could occur for a single
patient. We also performed an analysis at the level of episodes
of mechanical ventilation (ie, a binary measure of VAE or VAP
at any time during an episode of mechanical ventilation, to
address the reliability of using VAE surveillance methods for
hospital reporting). We did not perform the analysis at the day
level (ie, a binary measure of VAE or VAP on each day of
mechanical ventilation) because the vast majority of days
would be negative for VAE/VAP, which in turn would generate
an overly positive estimate of agreement.
Interrater reliability was evaluated by estimating observed
agreement, agreement expected by chance (calculated as the
probability of random agreement based on the observed
probabilities of events according to each rater), and Cohen’s κ
statistics for pairwise comparisons.10 The scale used to inter-
pret the κ estimates was as follows: <0, less than chance
agreement; 0.01–0.20, slight agreement; 0.21–0.40, fair agree-
ment; 0.41–0.60, moderate agreement; 0.61–0.80, substantial
agreement; 0.81–0.99, almost perfect agreement.11 We esti-
mated 95% conﬁdence intervals using bootstrapping methods.
All statistical analyses were performed using Stata 12.0
(StataCorp, College Station, TX). The study was approved by
the institutional review board at each participating hospital.
results
The study included a total of 30 patients from each of 5 par-
ticipating centers for a total of 150 patients with 150 episodes
of mechanical ventilation spanning 2,500 ventilator days.
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Characteristics of patients and outcomes of mechanical
ventilation are summarized in Table 1. The 150 episodes of
mechanical ventilation included 93 VAEs and 32 traditionally
deﬁned VAPs (according to the primary study RAs and
infection preventionists, respectively), as well as 38 episodes
that included neither a VAE nor a VAP.
Reliability of VAE and VAP Surveillance Deﬁnitions
Interrater reliability for VAEs including the timing of the event
was high (Table 2), with agreement of 86% and κ of 0.71 (95%
CI, 0.59–0.81). Interrater reliability for VAE at any time during
an episode of mechanical ventilation (ie, ignoring whether the
identiﬁed events were within 2 days of each other) was also
high, with agreement of 93% and κ of 0.86 (95% CI,
0.78–0.94). Agreement on the raw clinical data used for VAE
assessment was almost perfect. Values of κ ranged from 0.90
(95% CI, 0.85–0.94) for daily minimum white blood cell count
to 0.94 (95% CI, 0.92–0.95) for daily maximum temperature
to 0.97 (95% CI, 0.95–0.98) for daily maximum white blood
cell count. Agreement between the IPs using the NHSN
traditional VAP criteria was slight (κ, 0.12; 95% CI, −0.05–0.29).
Correlation of VAEs with Clinical Assessments
Among patients who met criteria for a VAE according to the
study RA, the most common causes identiﬁed by intensivists
table 1. Patient Characteristics (N= 150)
Characteristic Data





Cardiac arrest, % 9
Altered level of consciousness, % 8
Community-acquired pneumonia, % 5
Trauma, % 4
Sepsis, % 4
Hospital-acquired pneumonia, % 3
Asthma/COPD, % 3
Airway protection, % 3
ARDS, % 2
Other, % 10
SOFA score, median (IQR) 10 (8–13)
Outcomes
No. of days of mechanical ventilation, median (IQR) 13 (9–20)
VAP (according to hospital IP), % 21
VAC (according to study RA), % 63
Mortality, % 51
NOTE. IQR, interquartile range; COPD, chronic obstructive pulmon-
ary disease; ARDS, acute respiratory distress syndrome; SOFA,
sequential organ failure assessment; VAP, ventilator-associated
pneumonia; IP, infection preventionist, VAC, ventilator-associated
condition; RA, research assistant.










RA 1 VAE present 83 10 86 52 0.71
(0.59–0.81)










IP 1 VAP present 13 18 66 62 0.12
(−0.053–0.29)










Intensivist 1 VAP present 14 15 83 75 0.34
(0.17– 0.51)
Intensivist 1 VAP absent 21 164 … … …
NOTE. RA, research assistant; IP, infection preventionist.
aThe number of events identiﬁed by each reviewer and the agreement between reviewers are summarized.
bPanel A illustrates interrater reliability between 2 RAs for VAE assessment; a total of 161 events (106 VAEs identiﬁed by 1 or both RAs and
55 patients with no events) were included in κ estimates.
cPanel B illustrates interrater reliability between 2 IPs for traditionally deﬁned VAP; a total of 161 events (67 VAPs identiﬁed by 1 or both IPs and
94 patients with no VAP) were included in κ estimates.
dPanel C illustrates interrater reliability between 2 intensivists for clinical VAP as the cause for respiratory deterioration; a total of 214 events
(including 179 events of respiratory deterioration identiﬁed by 1 or both intensivists and 35 patients with no events according to either
intensivist) were included in κ estimates.
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were VAP (13%–15%), acute respiratory distress syndrome
(ARDS) (11%–12%), sepsis (4%–5%), aspiration (3%–6%),
and atelectasis (2%–8%) (Table 3). However, 44%–45% of
VAEs identiﬁed by RAs were not recognized by intensivist
reviewers as episodes of pulmonary deterioration at all.
Conversely, intensivists identiﬁed a higher total number of
episodes of pulmonary deterioration overall than study RAs
(179 episodes vs 93 VAEs).
There was fair agreement between intensivists on whether or
not patients suffered an episode of pulmonary deterioration
from any cause (κ, 0.22; 95% CI, 0.05–0.39). There was also
fair agreement between intensivists on the clinical diagnosis of
VAP (κ, 0.34; 95% CI, 0.17–0.51) (Table 2). Agreement
regarding the cause for respiratory deterioration identiﬁed by
intensivists was quite variable, with κ ranging between −0.007
and 0.798 (Table 4).
discussion
Within a multicenter prospective study of VAE surveillance,
agreement between research assistants on the identiﬁcation of
VAEs was high overall and was also high for the individual
elements used to deﬁne VAEs. Consistent with previous
literature, agreement between trained IPs using traditional
surveillance deﬁnitions for VAP was slight, at best.3,5,12,13
Agreement between intensivists on the clinical diagnosis of
VAP was only fair. Intensivists also disagreed with one another
on whether patients suffered episodes of pulmonary
deterioration at all, and there was poor overlap between
intensivists’ perceptions of pulmonary deterioration and VAE
criteria. Many VAEs were not identiﬁed as deterioration events
by intensivist reviewers, and many deterioration events
identiﬁed by intensivists did not meet VAE criteria.
Given that these surveillance methods are intended for
quality measurement and improvement and hospital perfor-
mance evaluation, the improved objectivity, reliability, and
potential ease of data capture from electronic medical records
represent an improvement over the previous surveillance
methods, which were more subjective and prone to disagree-
ment.2 That this study conﬁrmed high agreement between
RAs, even when using different surveillance strategies (eg, real-
time data capture versus retrospective chart review), which
provides reassurance that some of the goals of this revised
algorithm have been met.
Our ﬁndings are also consistent, however, with previous
literature suggesting a disconnect between objective surveil-
lance and clinical evaluations.2,14 The surveillance deﬁnitions
both miss events that clinicians identify as pulmonary dete-
rioration and capture events that are not identiﬁed as such.
Clinicians themselves, however, frequently disagreed with each
other regarding whether or not patients suffered episodes of
pulmonary deterioration. These discrepancies likely have sev-
eral causes, including the lack of speciﬁcity for most clinical
signs of pulmonary disease. In addition, retrospective chart
review rather than prospective bedside evaluation may have
magniﬁed uncertainty and differences of opinion between
intensivists. Finally, intensivists’ clinical assessments in general
may be nuanced and inherently more uncertain than decisions
made for surveillance.
















Pneumothorax 3 2 2 0.798
Cardiac arrest 2 1 1 0.665
Aspiration 10 12 6 0.521
Pulmonary
hemorrhage
2 2 1 0.495
Sepsis 16 15 8 0.478
Atelectasis 16 13 6 0.371
VAP 29 35 14 0.340
ARDS 19 19 6 0.249
CHF 8 11 2 0.175
Pulmonary
embolism
0 2 0 0.000
SIRS 2 1 0 −0.006
Cancer 1 3 0 −0.007
Other 24 24 9 0.296
Unknown 7 4 1 0.162
NOTE. VAP, ventilator-associated pneumonia; ARDS, acute respiratory
distress syndrome; CHF, congestive heart failure; SIRS, systemic
inﬂammatory response syndrome.
aA total of 214 events (including 179 events of respiratory deteriora-
tion identiﬁed by 1 or both intensivists and 35 patients with no events
according to either intensivist) were included in κ estimates.
table 3. Primary Diagnoses According to Intensivists for






No. of Cases κ Value
No deterioration present 41 42 0.717
VAP 14 12 0.553
ARDS 10 11 0.410
Aspiration 3 6 0.652
Atelectasis 7 2 0.425
Cardiac arrest 1 1 1.000
CHF 2 4 −0.030
Sepsis 5 4 0.417
Cancer 0 2 0.000
Pneumothorax 1 0 0.000
Other 6 7 0.421
Unknown 3 2 −0.027
NOTE. VAP, ventilator-associated pneumonia; ARDS, acute respiratory
distress syndrome; CHF, congestive heart failure.
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Our study has several important strengths. It was nested
within a large, multicenter study of VAE surveillance, allowing
for a broad case mix for study. It is one of only a few studies
with such a high number of charts reviewed for VAP diagnosis,
and it is the only study to our knowledge that included
reviews by 3 different stakeholders in VAE and VAP surveil-
lance: RAs for VAEs, IPs for NHSN VAPs, and intensivists for
clinical causes of respiratory deterioration. The current study
is therefore a rich source of data on how perspectives vary
between and among these key stakeholders in hospital
surveillance.
Our study also has several limitations. First, as a multicenter
study, each site had some liberty to perform surveillance in
ways that were feasible. For example, some centers were able to
collect some surveillance data elements automatically through
electronic medical records, whereas others required complete
hand collection by RAs. Furthermore, the conditions for
reviewers sometimes differed within reviewer pairs. For
example, one reviewer might have collected data in a pro-
spective manner and possibly directly on-site in the study
ICUs, whereas the other reviewer in a pair might have collected
data retrospectively, with access to data from the entire
admission. Despite these differences, interrater reliability
between research assistants was high, indicating that the
surveillance deﬁnitions do not appear to be heavily compro-
mised by different collection strategies. A second limitation is
that because events and diagnoses were generally rare, agree-
ment expected by chance alone was high (because of the high
nonevent rates); this was particularly so in the analyses of the
interrater reliability among intensivists, where many events of
pulmonary deterioration were identiﬁed but few were attrib-
uted to VAP. Therefore, κ estimates were frequently low even
when observed agreement was relatively high; these numbers
should be interpreted with caution.
In summary, the reliability of VAE assessment is sig-
niﬁcantly better than the prior CDC VAP surveillance deﬁni-
tions and better than interobserver agreement between
intensivists. However, discrepancies between VAE surveillance
and clinical impressions still exist. The clinical signiﬁcance of
these differences and their impact on quality improvement
efforts are unclear. On the one hand, VAE was not intended for
clinical diagnosis or clinical management but rather to help
identify general sources of harm for patients at the population
level. VAE deﬁnitions include a built-in threshold effect to
detect only severe events (ie, complications severe enough to
precipitate a sustained increase in ventilator settings). It is
therefore understandable and predictable that VAE surveil-
lance will miss some sources of respiratory deterioration
identiﬁed by clinicians. This can be an advantage for quality
improvement practitioners because it helps them to focus their
efforts only on severe complications. On the other hand,
clinicians ﬁnd mismatches between surveillance events and
clinical events to be disturbing and a cause to question the
clinical relevance of surveillance. This tension between popu-
lation surveillance using quality improvement metrics versus
clinical diagnosis and management has not been resolved by
the transition to VAE surveillance and merits further evalua-
tion and better understanding before these measures can be
deemed suitable for public reporting or benchmarking.
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